Sucampo Files Patent Infringement Lawsuit Against Anchen Pharmaceuticals and Par Pharmaceuticals

  Sucampo Files Patent Infringement Lawsuit Against Anchen Pharmaceuticals and
  Par Pharmaceuticals

Business Wire

BETHESDA, Md. -- February 8, 2013

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it, its
affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited
(Takeda), and certain affiliates of Takeda have filed a patent infringement
lawsuit in the United States District Court for the District of Delaware
against Anchen Pharmaceuticals, Inc., Par Pharmaceuticals, Inc. and Par
Pharmaceutical Companies, Inc. (collectively, Anchen) related to an
Abbreviated New Drug Application (ANDA) that Anchen filed with the U.S. Food
and Drug Administration (FDA) to market a generic version of AMITIZA^®
(lubiprostone) oral capsules, 8 mcg and 24 mcg. The lawsuit claims
infringement of six patents that are listed in the FDA’s Orange Book and that
are scheduled to expire between 2020 and 2027.

Sucampo commenced the lawsuit within 45 days from the receipt of a Notice
letter sent by Anchen, dated December 26, 2012, regarding its filing of its
ANDA. Under the Hatch-Waxman Act, as a result of the patent infringement
lawsuit, final FDA approval of Anchen’s ANDA will be stayed up to 30 months
from the January 2, 2013 date of receipt of the Notice letter.

“Sucampo’s patent estate for AMITIZA^® is strong, and the company intends to
vigorously defend our intellectual property. We believe that the AMITIZA^®
patents, granted by the US Patent & Trademark Office, are valid, enforceable,
and infringed by Anchen’s proposed lubiprostone products,” said Thomas J.
Knapp, Executive Vice President, Chief Legal Officer, and Corporate Secretary
of Sucampo.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman,
Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones,
naturally occurring fatty acid metabolites that have emerged as promising
compounds with unique physiological activities, can be targeted for the
treatment of unmet or underserved medical needs. For more information, please
visit www.sucampo.com.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
US and internationally and the exposure to litigation and/or regulatory
actions. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk factors
and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which
the Company incorporates by reference.

Contact:

Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
staylor@sucampo.com
 
Press spacebar to pause and continue. Press esc to stop.